Peer-Reviewed Publications

The publications listed below highlight key milestones in the development of Bellicum’s technologies and product candidates, from recent clinical developments back to early discovery. The list is not intended to be exhaustive.

• Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, GrilleyB, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, and Brenner MK. Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy. The New England Journal of Medicine 2011; 365:1673-1683.
• Sadelain M: Eliminating Cells Gone Astray. The New England Journal of Medicine 2011; 365:1735-1737.
• Narayanan N, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM: A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. Journal of Clinical Investigation doi:10.1172/JCI44327.
• Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G: An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells 28(6):1107-15 (2010).
• Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM: Enhanced activation of human dendritic cells by inducible CD40 and TLR4 ligation. Cancer Research 67(21): 10528-10537 (2007).
• Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM: Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nature Medicine 11(2):130-137 (2005).
• Straathof K, Pulè M, Yotnda P, Dotti G, Vanin E, Brenner M, Heslop H, Spencer DM, Rooney C: An inducible caspase 9 safety switch for cell therapy. Blood 105:11, 4247-4254 (2005).
• Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T and Berger HJ: Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. Journal of Clinical Pharmacology 41, 870-879 (2001).
• Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM: Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 61, 6795-6804 (2001).
• Fan L, Freeman KW, Khan T, Pham E, and Spencer DM: Improved artificial death switches based on caspases and FADD. Human Gene Therapy 10, 2273-2285 (1999).
• MacCorkle RA, Freeman KW, and Spencer DM: Synthetic activation of caspases: Artificial death switches. PNAS 95, 3655-3660; commentary: PNAS 95, 5421-5412 (1998).
• Amara JF, Clackson T, Rivera VM, Guo T, Keenan T, Natesan S, Pollock R, Yang W, Courage NL, Holt DA, Gilman M: A versatile synthetic dimerizer for the regulation of protein-protein interactions. PNAS 94, 10618-10623 (1997).
• Spencer DM, Belshaw P, Chen L, Ho SN, Randazzo F, Crabtree GR, Schreiber SL: Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Current Biology 6, 839-847(1996).
• Spencer DM, Wandless TL, Schreiber SL, Crabtree GR: Controlling signal transduction with synthetic ligands. Science 262(5136), 1019-1024 (1993).